NICE changes its mind on rare bile duct cancer drug from IncyteIncyte’s Pemazyre has become the first targeted therapy available for NHS patients with cholangiocarcinoma or bile duct cancer, Share XNICE changes its mind on rare bile duct cancer drug from Incytehttps://pharmaphorum.com/news/nice-changes-its-mind-on-rare-bile-duct-cancer-drug-from-incyte/
FDA approves Incyte’s Pemazyre for rare bile duct cancerThe FDA has approved Incyte’s Pemazyre (pemigatinib), the first targeted treatment for a rare cancer of the bile Share XFDA approves Incyte’s Pemazyre for rare bile duct cancerhttps://pharmaphorum.com/news/fda-approves-incytes-pemazyre-for-rare-bile-duct-cancer/
